Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$940K Buy
2,873
+1,296
+82% +$411K 0.25% 74
2025
Q3
$445K Buy
1,577
+53
+3% +$15.4K 0.12% 128
2025
Q2
$426K Sell
1,524
-399
-21% -$113K 0.13% 130
2025
Q1
$599K Buy
1,923
+688
+56% +$203K 0.19% 83
2024
Q4
$322K Buy
1,235
+582
+89% +$173K 0.12% 126
2024
Q3
$210K Buy
+653
New +$214K 0.08% 163
2024
Q1
Sell
-1,614
Closed -$465K 154
2023
Q4
$465K Buy
1,614
+274
+20% +$74.7K 0.21% 91
2023
Q3
$360K Buy
+1,340
New +$334K 0.17% 91

Other funds holding AMGN

Rovin Capital's AMGN Position: Q4 2025 in Review

Rovin Capital increased its Amgen (AMGN) stake by 82% in Q4 2025, buying an estimated $411K and bringing the position to 2,873 shares worth $940K. The position accounts for 0.25% of the portfolio, ranked #74.

Rovin Capital first reported a position in AMGN in Q3 2023 and has held it in 8 quarters since. 3,084 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

  • Rovin Capital held 2,873 shares of Amgen worth $940K as of Q4 2025.
  • Rovin Capital bought 1,296 Amgen shares in Q4 2025, an estimated $411K.
  • Amgen made up 0.25% of Rovin Capital's portfolio in Q4 2025, its #74 holding.
  • Rovin Capital first reported a position in Amgen in Q3 2023 and has held it in 8 quarters since.
  • 3,084 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Rovin Capital's 13F filing for Q4 2025, filed 9 Feb 2026.